Founded in 2000, Lexington, Massachusetts-based Synta
Pharmaceuticals focuses on the development of its oncology medicines. The
company’s main product ganetespib, is an Hsp90 inhibitor used in the treatment
of lung cancer, breast cancer, acute myeloid leukemia, myelodysplastic syndrome,
ovarian cancer, and refractory sarcoma. Hsp90 Drug Conjugate is the company’s
proprietary, small molecule cancer drug development program. The company has
several drugs in phase 2 and phase 3 clinical trials, as well as some just
starting out in the phase 1 stage.
When developing pharmaceuticals, it is vital to have a team
of experts helping navigate the highly complicated and very involved waters of
the development process. To this accord, Synta Pharmaceuticals recently
announced the formation of its Expert Oncology Panel:
David E. Avigan, M.D. – chief section of Hematological
Malignancies and Bone Marrow Transplantation, Beth Israel Deaconess Medical
Center associate professor, Medicine, Harvard Medical School
Bruce Allan Chabner, M.D. – director of Clinical Research,
Cancer Center Massachusetts General Hospital Cancer Center
Jeffrey A. Engelman, M.D., Ph.D. – director, Center for
Thoracic Cancers Massachusetts General Hospital Cancer Center, associate
professor of Medicine Harvard Medical School
F. Stephen Hodi, Jr., M.D. – director, Melanoma Center
Director, Center for Immuno-Oncology, associate professor of Medicine Harvard
Medical School, Dana Farber Cancer Institute
Martin J. Murphy, D. MedSc, Ph.D., FASCO – chairman and
chief executive officer AlphaMed Consulting, Inc.
Neil Lee Spector, M.D. – associate professor of Medicine,
Sandra Coates associate professor, associate professor of Pharmacology &
Cancer Biology, member of the Duke Cancer Institute
Cancer costs the world more money than any other disease,
according to the American Institute of Cancer Research (AICR), racking up
annual costs of $895 billion. More than half a million Americans die of cancer
every year, making the disease the second-leading cause of death in the United
States. Comparatively, heart disease costs $753 billion while traffic accidents
and diabetes each cost about $204 billion.
Statistics like these drive companies like Synta
Pharmaceuticals to aggressively usher their products to market and race toward
eliminating the disease. By building a panel consisting of world-renown doctors
and experts in the oncology field, Synta Pharmaceuticals has already taken a
progressive step in the process of getting a new potentially life-saving drug
into the hands of cancer patients.
Stay tuned as we follow the company’s progress along, as it
is cashed up and recently cut staff back to 33 employees in order to maintain
operations until at least the middle of 2017.
For more information, visit http://www.syntapharma.com/
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
